LBA31
Start here
The phase 3 PRABITAS trial enrolled 970 patients with refractory metastatic colorectal cancer and tested a biweekly FTD/TPI plus bevacizumab regimen against the conventional regimen. The biweekly schedule was non-inferior for overall survival, with a median OS of 11.3 months versus 10.3 months (HR 0.93, 95% CI 0.80-1.08; non-inferiority P<0.0001). Superiority over the conventional regimen was not demonstrated. The biweekly regimen was also associated with fewer hematologic adverse events, suggesting a better tolerated option for this heavily pretreated population. Open questions include whether the efficacy and safety findings will translate into regulatory review or changes to standard practice in refractory metastatic colorectal cancer.
Written by a model from the reports · updated 3 hours ago
Coverage timeline
Follow the coverage to see the different angles.
- mp.weixin.qq.comPhase 3 PRABITAS: Biweekly FTD/TPI Plus Bevacizumab Meets OS Non-Inferiority With Less Toxicity in Metastatic Colorectal Cancer
The phase 3 PRABITAS study showed that a biweekly FTD/TPI plus bevacizumab regimen was non-inferior to the conventional regimen for overall survival in metastatic colorectal cancer, with fewer hematologic adverse events. The study enrolled 970 patients with refractory mCRC; median OS was 11.3 months with the biweekly regimen versus 10.3 months with the conventional regimen (HR 0.93, 95% CI 0.80-1.08; non-inferiority P<0.0001), but superiority was not shown.
- x.com#ESMO26 | LBA31
Heat trend for this story
Heat now 14·Peak in the comparable set 17 (Oct 24 23:00)·Change over 24h in the comparable set +57%·Participants now 3
Participants counted above, heat below. The trend compares only the participants observed in full throughout, so its set can be smaller than the heat figure itself. Move the pointer or click the chart for an hour's reading; the left and right arrow keys work too.